Doctor Operating CT Scanner
Worth More Than 4%



With your donations Wings for Ewing Sarcoma  is able to fund childhood cancer research projects for Ewing Sarcoma to further advance treatments protocols. Grants are reviewed, so you can trust that the money you give to this non-profit organization are used for beneficial and life-changing purposes. With your help we will be able to meet our mission goal and develop a plan that meets the demands for funding Ewing Sarcoma Research. 


2020 Research Grants:


September 2020 - $10,000 Research Grant for Ewing Sarcoma Research to Dr. Brian Crompton at Dana-Farber Cancer Institute in Boston. 

Dr. Brian Crompton is a physician-scientist at Dana-Farber Cancer Institute and his research focuses on finding new treatment approaches for patients with Ewing sarcoma who do not respond to the first line of treatment of VCD / IE chemotherapy or relapse patients. 

Dr. Brian Crompton and the Research Team at the Crompton Laboratory at Dana-Faber Cancer Institute (Pictures courtesy of Dr. Brian Crompton and Dana-Faber Cancer Institute)

In recent years, Dr. Crompton has found that Ewing sarcoma cancer cells are dependent on the activity of a protein called focal adhesion kinase also known as FAK. When FAK is inhibited, Ewing sarcoma cells die and cannot form tumors. Dr. Crompton is now partnering with a major pharmaceutical company that has multiple FAK inhibitors in clinical trials for adult tumors to complete necessary experiments to test the effects of FAK inhibition in a clinical trial for patients with Ewing sarcoma.


A few words from Dr. Crompton, “We are so excited to embark on a partnership with one of our heroes, Chiara Valle and her foundation, Wings for Ewing Sarcoma. We know that to break the trend of slow incremental progress in cancer care, we need to take on bold new research challenges. Together with Wings for Ewing Sarcoma, we will be able to test bold new ideas in the laboratory and then look to translate our findings into new treatment strategies for patients with Ewing Sarcoma.

In the Crompton laboratory, we use high-throughput screening assays to identify novel combinations of targeted therapies, such as tyrosine kinase inhibitors, that work together to kill Ewing sarcoma cancer cells. Our screening approach treats cancer cells growing in culture dishes with drugs combined using a robotic liquid handling platform. Each candidate drug combination is tested against cell lines grown from Ewing sarcoma tumors donated by multiple patients. In this way, we hope to identify combinations that work for as many patients with Ewing sarcoma as possible. Once we identify potent treatment combinations, our goal is to work with our colleagues in the clinical research field to develop clinical trials to test the efficacy of these combinations for patients.

The Crompton laboratory also specializes in utilizing novel DNA sequencing technologies to develop new non-invasive tests that can diagnose patients with Ewing sarcoma, predict their likelihood of treatment response, and identify relapses earlier than they can be detected with radiologic scans. These assays use a simple blood draw to detect the presence of minute amounts of tumor material floating in the blood of patients with cancer. Our first goal is to demonstrate that these “blood biopsies” are accurate and predictive. Once these tests are validated, our goal is to make these tests available in the clinic to improve decision making for to patients and their doctors.”

We are very excited to see how Dr. Crompton’s research progresses from here on and will share some updates down the road. Thank you for your support. This would not have been possible without you!  View acknowledgement letter from Dana-Faber Cancer Institute.